What does Aldeyra Therapeutics, Inc. do?
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic…
What is Aldeyra Therapeutics, Inc.'s P/E and P/B ratio?
Aldeyra Therapeutics, Inc. has a P/E ratio of -1.7 and a P/B ratio of 1.03.
What is Aldeyra Therapeutics, Inc.'s debt-to-equity ratio?
Aldeyra Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Aldeyra Therapeutics, Inc. owe compared with what it owns?
Aldeyra Therapeutics, Inc. owes $0.20 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Aldeyra Therapeutics, Inc.'s Positivity rank?
Aldeyra Therapeutics, Inc. is ranked #1,269 of 6,775 companies globally and #242 of 4,000 in United States on PositoAI, with a Positivity Score of 23,081.
Does Aldeyra Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Aldeyra Therapeutics, Inc..
Where can I read the latest news about Aldeyra Therapeutics, Inc.?
Recent headlines about Aldeyra Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Aldeyra Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Aldeyra Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.